Georgia CTSA Investigator Leads Discovery of Biomarker for Tracking Treatment Responses in Chronic Lymphocytic Leukemia

“Indeed, the percentage of CLL cells that have PD-1 in the blood correlated with BTKi treatment response and progression,” says study lead Andres Chang, MD, PhD. “This suggests that PD-1 expression could be a useful biomarker to predict response and resistance to BTKi therapy. Additionally, eliminating CLL cells that express PD-1 could be a potentially useful therapeutic strategy.” Chang is a Georgia CTSA MSCR student and Pilot Grant Recipient.